Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1988-10-3
|
pubmed:abstractText |
The cytotoxicity of spleen lymphocytes of C57BL/6 mice is augmented both by incubation of spleen lymphocytes with human recombinant interleukin-2 (rIL-2) in vitro (LAK cell) and by systemic administration of high doses of rIL-2 into C57BL/6 mice for more than 3 consecutive days. In this study, the precursors and effectors of LAK cells and the cytotoxic cells induced by systemic administration of rIL-2 were characterized by using anti-asialoGM1 and anti-Thy1.2 antibody. The in vitro induced LAK cells were demonstrated to be derived partly from asialoGM1 negative cells and the cytotoxicities of LAK cells induced in vitro with rIL-2 were partially resistant to lysis by anti-asialoGM1 antibody plus complement in comparison with NK cells. Contrary to this, the cytotoxicities of spleen lymphocytes of C57BL/6 mice pretreated with anti-asialoGM1 antibody were not augmented by in vivo injection of rIL-2. In addition, the cytotoxic activities of spleen lymphocytes, augmented by systemic administration of rIL-2, were completely suppressed by anti-asialoGM1 antibody and complement in vitro. These findings indicate that the cytotoxic lymphocytes induced in vivo by systemic administration of rIL-2 are different from in vitro induced LAK cells and have the same surface phenotype as NK cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0277-5379
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1055-60
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:3261691-Animals,
pubmed-meshheading:3261691-Cells, Cultured,
pubmed-meshheading:3261691-Cytotoxicity, Immunologic,
pubmed-meshheading:3261691-Interleukin-2,
pubmed-meshheading:3261691-Killer Cells, Natural,
pubmed-meshheading:3261691-Lymphocyte Activation,
pubmed-meshheading:3261691-Lymphocytes,
pubmed-meshheading:3261691-Male,
pubmed-meshheading:3261691-Melanoma,
pubmed-meshheading:3261691-Mice,
pubmed-meshheading:3261691-Mice, Inbred C57BL,
pubmed-meshheading:3261691-Spleen,
pubmed-meshheading:3261691-Tumor Cells, Cultured
|
pubmed:year |
1988
|
pubmed:articleTitle |
The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.
|
pubmed:affiliation |
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|